HIV/SARS-CoV-2 coinfection: A global perspective

J Med Virol. 2021 Feb;93(2):726-732. doi: 10.1002/jmv.26321. Epub 2020 Jul 28.

Abstract

Since its first appearance in Wuhan, China, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread throughout the world and has become a global pandemic. Several medical comorbidities have been identified as risk factors for coronavirus disease 2019 (COVID-19). However, it remains unclear whether people living with human immunodefeciency virus (PLWH) are at an increased risk of COVID-19 and severe disease manifestation, with controversial suggestion that HIV-infected individuals could be protected from severe COVID-19 by means of antiretroviral therapy or HIV-related immunosuppression. Several cases of coinfection with HIV and SARS-CoV-2 have been reported from different parts of the globe. This review seeks to provide a holistic overview of SARS-CoV-2 infection in PLWH.

Keywords: COVID-19; HIV; antiretroviral therapy/coinfection; immunodeficiency.

Publication types

  • Review

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active / statistics & numerical data
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / virology
  • COVID-19 / epidemiology*
  • COVID-19 / immunology
  • COVID-19 / mortality
  • COVID-19 / virology
  • Coinfection
  • Comorbidity
  • Diabetes Mellitus / epidemiology
  • Diabetes Mellitus / physiopathology
  • Female
  • HIV / drug effects
  • HIV / growth & development
  • HIV / pathogenicity
  • HIV Infections / drug therapy
  • HIV Infections / epidemiology*
  • HIV Infections / mortality
  • HIV Infections / virology
  • Humans
  • Hypertension / epidemiology
  • Hypertension / physiopathology
  • Immunocompromised Host*
  • Male
  • Middle Aged
  • Pandemics*
  • SARS-CoV-2 / immunology
  • SARS-CoV-2 / pathogenicity*
  • Survival Analysis
  • Treatment Outcome

Substances

  • Anti-HIV Agents